Archived explainer. For the current picture see today's QURE page.
UNIQURE N V (QURE) is up +14.38% in the latest session. Our newswire has captured 8 stories on QURE across 5 sources in the last 36 hours, with AI sentiment reading mixed (avg 56/100).
QURE stock surged 14.38% to $41.93 on Monday, driven by the biotech firm's recent progress on its AMT-130 program and extended cash runway. The company reported Q2 2026 results that included a revenue beat and confirmed plans to file a Biologics License Application (BLA) for AMT-130 in the third quarter. These developments reinforced investor confidence in the firm’s regulatory and financial positioning.
UniQure outlined its plans for the BLA submission for AMT-130, a gene therapy candidate for Huntington’s disease, during its Q2 2026 earnings call on July 29. The company confirmed alignment with the FDA on the accelerated-approval pathway and confirmed trial plans. Additionally, UniQure extended its cash runway to 2030, supported by a strengthened balance sheet and $5.84 million in Q2 revenue, which beat estimates by $0.46 million. Despite a GAAP EPS of -$1.22, which missed expectations by $0.42, the company highlighted progress across its pipeline, including top-line data expected from a Phase I/II study of AMT-130.
The stock opened at $37.00, a 0.9% gap up from the prior close, and reached an intraday high of $42.00 shortly after the market opened. Trading volume of 2.2 million shares was 1.1 times the 3-month average. The stock had fallen 9.4% over the previous eight sessions, closing at $36.66 on Friday. Over the past 90 days, insiders have sold 20 times, totaling $17.9 million, with the most recent filing on July 7.
UniQure has no scheduled earnings date in the immediate future. Investors should monitor the BLA submission for AMT-130 in Q3 2026 and the top-line data from the four-year Phase I/II study. Coverage breadth and analyst commentary will also be key indicators of market sentiment.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Not financial advice.
uniQure (QURE) Q2 2026 earnings call: FDA aligns on AMT-130 accelerated-approval BLA, confirmatory trial plans, cash runway to 2030—read now.
uniQure N.V. (QURE) Q2 2026 Earnings Call July 29, 2026 8:30 AM EDTCompany ParticipantsChiara Russo - Senior Director of Investor RelationsMatthew Kapusta -...
uniQure’s Q2 2026 results spotlight a fortified balance sheet and imminent regulatory milestones for AMT-130 in Huntington’s disease, while clinical programs for epilepsy and Fabry disease advance with promising data and manageable safety. Cash runway now extends into 2030, funding key launches and research.
UniQure reports Q2 revenue beat, extends cash runway to 2030
uniQure (QURE) Q2 earnings: GAAP EPS -$1.22 missed by $0.42 while revenue $5.84M (+11% YoY) beat by $0.46M.
Filed: 2026-07-29 AccNo: 0001104659-26-087808 Size: 311 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
~ U.S. and U.K. regulatory submissions for AMT-130 for Huntington’s disease on track as planned for the third quarter of 2026 ~ ~ Topline four-year data from the Phase I/II study of AMT-130 expected in...
uniQure (QURE) reports Q2 earnings July 29 before open. See consensus EPS -$0.81, revenue $5.38M, and estimate revisions.
More on QURE: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier QURE move explainers: 2026-07-30 · 2026-07-29